Laurus Labs Ltd
NSE:LAURUSLABS

Watchlist Manager
Laurus Labs Ltd Logo
Laurus Labs Ltd
NSE:LAURUSLABS
Watchlist
Price: 512.6 INR 4.79% Market Closed
Market Cap: 276.4B INR
Have any thoughts about
Laurus Labs Ltd?
Write Note

Laurus Labs Ltd
Equity Earnings Affiliates

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Laurus Labs Ltd
Equity Earnings Affiliates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Equity Earnings Affiliates CAGR 3Y CAGR 5Y CAGR 10Y
Laurus Labs Ltd
NSE:LAURUSLABS
Equity Earnings Affiliates
-â‚ą39.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Equity Earnings Affiliates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Equity Earnings Affiliates
-â‚ą44.7m
CAGR 3-Years
23%
CAGR 5-Years
37%
CAGR 10-Years
18%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Equity Earnings Affiliates
-â‚ą194.2m
CAGR 3-Years
-4%
CAGR 5-Years
-15%
CAGR 10-Years
-21%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Equity Earnings Affiliates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Equity Earnings Affiliates
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Laurus Labs Ltd
Glance View

Market Cap
276.3B INR
Industry
Pharmaceuticals

Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The company is headquartered in Hyderabad, Telangana and currently employs 5,131 full-time employees. The company went IPO on 2016-12-19. The firm is a manufacturer of active pharmaceutical ingredients (API) for antiretroviral (ARV), oncology, cardiovascular, antidiabetics, anti-asthma and gastroenterology. The company also develops and manufactures oral solid formulations, which provide contract research and manufacturing services (CRAMS) to other global pharma companies, and produce specialty ingredients for nutraceuticals, dietary supplements and cosmeceuticals. The firm operates through four business units covering a range of therapeutic applications, including Generics API, which is engaged in the development, manufacture and sale of APIs and advanced intermediates; Generics Finished Dosage Form (FDF), which is engaged in the development and manufacture of oral solid formulations; Synthesis, which is a key starting materials, intermediates and APIs for New Chemical Entities (NCEs), and Bio, which is engaged in the recombinant products.

LAURUSLABS Intrinsic Value
377.2 INR
Overvaluation 26%
Intrinsic Value
Price

See Also

What is Laurus Labs Ltd's Equity Earnings Affiliates?
Equity Earnings Affiliates
-39.5m INR

Based on the financial report for Jun 30, 2024, Laurus Labs Ltd's Equity Earnings Affiliates amounts to -39.5m INR.

What is Laurus Labs Ltd's Equity Earnings Affiliates growth rate?
Equity Earnings Affiliates CAGR 1Y
12%

Over the last year, the Equity Earnings Affiliates growth was 12%.

Back to Top